生物技术和制药行业的裁员：2025年2月按治疗和技术重点概述：-动脉网

Layoffs in Biotech and Pharma: A February 2025 Overview by Therapeutic and Technology Focus Related posts:

GeneOnline 等信源发布 2025-04-01 13:05



可切换为仅中文







by Bernice Lottering

伯尼斯·洛特林

Share To

分享到

我

n February 2025, the biotech and pharmaceutical sectors face a series of workforce reductions as companies grapple with financial constraints, pipeline adjustments, and operational realignments. From oncology to gene therapies and metabolic disorders, firms are resizing staff to match evolving priorities.

2025年2月，生物技术和制药行业面临一系列裁员，因为企业正在应对财务限制、研发管线调整和运营重组。从肿瘤学到基因治疗和代谢疾病，各公司正在调整员工规模以适应不断变化的优先事项。

These layoffs can be categorized by therapeutic and technological focus, detailing the companies, their assets, disease targets, and the reasons driving these changes, as reported throughout the month..

这些裁员可以按治疗和技术重点分类，详细列出公司、其资产、疾病目标以及推动这些变化的原因，正如整个月所报道的那样。

Oncology and Immuno-Oncology

肿瘤学与免疫肿瘤学

Oncology-focused

专注于肿瘤学的

companies are streamlining staff amid pipeline shifts and funding challenges

公司正在裁员，以应对渠道转移和资金挑战。

。

Lava Therapeutics, a clinical-stage immuno-oncology biotech with bases in Utrecht and Philadelphia, cuts 30% of its 37 employees—leaving about 25—while exploring a sale, merger, or acquisition. With $76.6 million in cash as of December 2024, Lava continues its Phase I trial of LAVA-1266, a bispecific gamma delta T-cell engager for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), after dropping its prostate cancer asset LAVA-1207 in December.

总部位于乌得勒支和费城的临床阶段免疫肿瘤生物技术公司 Lava Therapeutics 裁减了其 37 名员工中的 30%，剩下约 25 人，同时正在探索出售、合并或收购的可能性。截至 2024 年 12 月，该公司拥有 7660 万美元现金，并在放弃其前列腺癌资产 LAVA-1207 后继续进行 LAVA-1266 的 I 期试验，这是一种针对急性髓系白血病 (AML) 和骨髓增生异常综合征 (MDS) 的双特异性 γδ T 细胞接合器。

Repare Therapeutics in Montreal slashes 75% of its 179 staff, retaining fewer than 35, including the exit of Chief Medical Officer Maria Koehler by March 31. This follows a 25% cut in 2024, with Repare now prioritizing Phase I programs PLK4 inhibitor RP-1664 and Polθ ATPase inhibitor RP-3467 for cancer.

蒙特利尔的Repare Therapeutics公司裁员179名员工中的75%，仅保留不到35人，首席医疗官Maria Koehler也将在3月31日前离职。此前，该公司在2024年已削减了25%的员工，目前Repare正集中资源推进PLK4抑制剂RP-1664和Polθ ATPase抑制剂RP-3467的I期癌症研究项目。

。

Moreover, Viracta Therapeutics in Cardiff, California, shut down entirely, laying off all remaining staff—likely under 20 after prior cuts of 23% in August and 42% in November 2024—after halting its EBV+ lymphoma program in December and facing Nasdaq delisting in January. Frontier Medicines, a San Francisco and Boston-based precision medicine firm, reduces an unspecified number of staff to focus on its KRAS G12C dual inhibitor FMC-376, expecting Phase I/II interim data in late 2025 after an $80 million Series C in 2024.

此外，位于加利福尼亚卡迪夫的Viracta Therapeutics公司全面关闭，在2024年8月裁员23%、11月裁员42%之后，剩余员工（可能不到20人）全部被解雇。此前，该公司于12月暂停了其EBV+淋巴瘤项目，并在1月面临纳斯达克退市。总部位于旧金山和波士顿的精准医疗公司Frontier Medicines裁减了若干名员工，集中资源开发其KRAS G12C双重抑制剂FMC-376，并预计在2024年完成8000万美元C轮融资后，于2025年底获得一期/二期中期数据。

Kojin Therapeutics in Boston closes operations, affecting 25 employees, as funding dries up months from naming a lead small-molecule ferroptosis inducer for cancer and autoimmune diseases..

波士顿的Kojin Therapeutics公司停止运营，影响25名员工，此前数月该公司曾命名了一种用于癌症和自身免疫疾病的主要小分子铁死亡诱导剂，但如今资金枯竭。

Hematology and Blood Disorders

血液学与血液疾病

Companies targeting blood cancers and related disorders are resizing to stretch resources. Ryvu Therapeutics in Kraków, Poland, trims 30% of its workforce, leaving around 200 employees, to extend its $48.3 million cash pile into mid-2026. It focuses on three Phase II trials of RVU120 for AML, myelofibrosis, and MDS, suspending new enrollment in a fourth AML/MDS study, with data updates due in Q2.

针对血液癌症及相关疾病的企业正在调整规模以充分利用资源。波兰克拉科夫的Ryvu Therapeutics公司裁员30%，留下约200名员工，以将其4830万美元的现金储备延长至2026年中。该公司正集中于RVU120针对急性髓系白血病（AML）、骨髓纤维化和骨髓增生异常综合征（MDS）的三项II期试验，暂停了第四项AML/MDS研究的新患者招募，预计第二季度将提供数据更新。

Turnstone Biologics in La Jolla, California, cuts an undisclosed number of its 30 staff—after a 60% reduction in October 2024—as it halts its TIDAL-01 tumor-infiltrating lymphocyte therapy trials for colorectal, head and neck, and uveal melanoma cancers, exploring strategic alternatives like a merger or asset sale..

加利福尼亚州拉霍亚的特恩斯通生物制药公司裁减了其30名员工中数量不详的一部分——此前在2024年10月已裁员60%——因停止其针对结直肠癌、头颈癌和葡萄膜黑色素瘤的TIDAL-01肿瘤浸润淋巴细胞疗法试验，同时探索合并或资产出售等战略替代方案。

Gene Editing and Genetic Medicines

基因编辑与遗传医学

Gene-focused biotechs are adjusting headcounts as platforms falter or priorities shift. Spotlight Therapeutics in San Francisco shuts down, impacting over 40 staff at its peak, after its TAGE platform—a CRISPR-Cas delivery system for immuno-oncology and blood disorders—showed only 7% editing efficiency in mice per a December 2024 preprint.

基因聚焦的生物技术公司正在调整人员规模，因为其平台出现问题或优先事项发生转移。旧金山的Spotlight Therapeutics公司关闭，其巅峰时期影响了40多名员工。此前，该公司专注于免疫肿瘤学和血液疾病的CRISPR-Cas递送系统TAGE平台在小鼠实验中仅显示出7%的编辑效率，这一结果发表在2024年12月的预印本中。

Encoded Therapeutics in San Francisco lays off 29% of its roughly 200 employees, primarily in tech and early R&D, to stretch its runway to Q3 2026 and advance ETX101, a Dravet syndrome gene therapy, with preliminary Phase I data expected later in 2025. CRISPR Therapeutics, with sites in Boston, San Francisco, and Framingham, reduces an unspecified number of staff across science, research, and manufacturing roles, despite $1.9 billion in cash and strong demand for its Casgevy gene-editing therapy for sickle cell disease and beta-thalassemia, co-developed with Vertex..

旧金山的Encoded Therapeutics公司裁员约200名员工中的29%，主要集中在技术及早期研发部门，以将其资金储备延长至2026年第三季度，并推进其Dravet综合征基因疗法ETX101，预计将在2025年下半年获得初步的I期数据。而CRISPR Therapeutics尽管拥有19亿美元现金，并且与其合作伙伴Vertex共同开发的针对镰状细胞病和β-地中海贫血的Casgevy基因编辑疗法需求强劲，但仍在波士顿、旧金山和弗雷明汉的站点裁减了数量不详的科学、研究和制造岗位人员。

Metabolic and Inflammatory Diseases

代谢性和炎症性疾病

Firms in metabolic and inflammatory spaces are refocusing amid cash concerns. Inventiva in France halves its 115-person workforce in Q2 to concentrate solely on lanifibranor, a Phase III candidate for metabolic dysfunction-associated steatohepatitis (MASH), ending preclinical oncology work on YAP-TEAD interactions.

代谢和炎症领域的公司正在现金问题中重新调整重点。法国的Inventiva公司在第二季度将其115人的团队缩减一半，集中资源于三期候选药物lanifibranor，这是一种用于治疗代谢功能障碍相关脂肪性肝炎（MASH）的药物，同时停止了关于YAP-TEAD相互作用的临床前肿瘤学研究。

Fractyl Health cuts 17% of its 129 staff—22 people—to prioritize Revita, an endoscopic duodenal treatment, for a pivotal weight maintenance trial post-GLP-1 withdrawal, pausing its type 2 diabetes trial, while advancing its Rejuva gene therapy for pancreatic GLP-1 restoration into first-in-human studies.

Fractyl Health 裁减了其129名员工中的17%——即22人，以优先推进Revita（一种内镜下十二指肠治疗），用于GLP-1撤药后的关键体重维持试验，同时暂停了其2型糖尿病试验，并推进其Rejuva基因疗法（用于胰腺GLP-1恢复）进入首次人体研究。

。

Similarly, Third Harmonic Bio reduces 50% of its workforce to push THB335, an oral KIT inhibitor for chronic spontaneous urticaria, into Phase II, with $285 million in cash to last through June 2025. Q32 Bio in Waltham, Massachusetts, trims an undisclosed number of staff to extend its runway to mid-2026, focusing on bempikibart for alopecia areata in Phase II, while discontinuing its ADX-097 renal trial and exploring options for its complement inhibitor platform..

同样，Third Harmonic Bio将其员工人数减少50%，以推动其用于治疗慢性自发性荨麻疹的口服KIT抑制剂THB335进入二期临床试验，公司拥有2.85亿美元现金可支撑至2025年6月。位于马萨诸塞州沃尔瑟姆的Q32 Bio裁减了数量不详的员工，将其资金储备延长至2026年中，专注于处于二期临床试验的斑秃治疗药物bempikibart，同时终止了其ADX-097肾脏试验，并探索其补体抑制剂平台的选择。

Large Pharma: Operational Efficiency and Portfolio Shifts

大型制药公司：运营效率与投资组合调整

Major pharmaceutical players are shedding jobs to boost efficiency. Bristol Myers Squibb (BMS) continues its cost-cutting spree, targeting $2 billion in savings by 2027 atop a $1.5 billion goal by 2025. In February, BMS lays off 223 in Lawrenceville, New Jersey (effective May to August), 67 more there (April to December), and earlier cuts of 67, totaling 290 in the city this year after over 1,300 in 2024, as it streamlines management and prioritizes growth brands, ending partnerships with Immatics and Century Therapeutics.

大型制药公司正在裁员以提高效率。百时美施贵宝（BMS）继续其削减成本的行动，计划在2027年前实现20亿美元的节省，同时设定2025年前节省15亿美元的目标。今年2月，BMS在新泽西州劳伦斯维尔裁员223人（生效期为5月至8月），另外还有67人（4月至12月），加上此前裁减的67人，使得该市今年裁员总数达到290人，而2024年已裁员超过1300人。公司正精简管理、优先发展核心品牌，并终止与Immatics和Century Therapeutics的合作。

。

Then, Kyowa Kirin cuts 52 staff in Princeton, New Jersey, by May 1, aligning with its shift to a global research focus on antibodies and stem cell gene therapy, following an early retirement offer in 2024. Moderna trims 10% of its digital team—about 50 of 500 roles—as part of cost efficiencies, reporting $966 million in Q4 2024 revenue (down from $2.81 billion in 2023), aiming to cut R&D by $1.1 billion annually by 2027.

到5月1日，协和麒麟（Kyowa Kirin）将裁减其位于新泽西州普林斯顿的52名员工，此举旨在配合其向抗体和干细胞基因治疗的全球研究重点转型，并在2024年早些时候提出了提前退休计划。Moderna则削减了其数字团队10%的人员（约500个职位中的50个），作为降低成本的一部分；该公司报告称，其2024年第四季度收入为9.66亿美元（低于2023年的28.1亿美元），目标是到2027年每年减少11亿美元的研发支出。

Eisai reduces 121 U.S. staff (6.8%), including 57 in Nutley, New Jersey, by May, to optimize operations while targeting cancer, Alzheimer’s, and neurological conditions..

卫材公司将在5月前裁员121名美国员工（占6.8%），其中包括新泽西州纳特利的57人，以优化运营，同时专注于癌症、阿尔茨海默病和神经系统疾病。

Rare Diseases and Immunotherapies

罕见病与免疫疗法

Rare disease and immunotherapy biotechs are resizing to sustain key programs. X4 Pharmaceuticals lays off 43 of its 143 global staff—30%—closing its Vienna research center and pausing preclinical work to save $30-35 million, focusing on mavorixafor (Xolremdi) for WHIM syndrome after its FDA approval in 2024 and a $29.55 million Norgine licensing deal.

罕见病和免疫治疗生物技术公司正在调整规模以维持关键项目。X4制药公司裁员43人，占其全球员工总数143人的30%，关闭了维也纳研究中心并暂停了临床前工作，以节省3000万至3500万美元。公司集中资源于mavorixafor（Xolremdi），用于治疗WHIM综合症，该药物在2024年获得FDA批准，并达成了价值2955万美元的Norgine许可协议。

ImmunityBio cuts 10 California staff (nine in El Segundo, one in Culver City) by March 25, leaving around 630 of its 672 employees, while advancing Anktiva for bladder cancer into a Phase III NSCLC trial with BeiGene’s tislelizumab..

ImmunityBio在3月25日前裁员10名加州员工（九名在埃尔塞贡多，一名在卡尔弗城），留下约630名员工，同时推进Anktiva与百济神州的替雷利珠单抗联合用于膀胱癌的III期非小细胞肺癌试验。

Contract Research and Manufacturing Services

合同研究和制造服务

Service providers are adjusting to demand shifts. Charles River Laboratories closes its Durham County, North Carolina, site, laying off 31 by March 28, and trims an unspecified number at its Memphis, Tennessee, cell and gene therapy facility, after cutting over 1,300 staff since 2023 amid lower demand, reporting $1.01 billion in Q3 2024 revenue (down 1.6%).

服务提供商正在适应需求变化。查尔斯河实验室关闭了其位于北卡罗来纳州达勒姆县的基地，于3月28日前裁员31人，并在其田纳西州孟菲斯的细胞与基因治疗设施裁减了未具体说明数量的员工。自2023年以来，由于需求下降，公司已裁员超过1,300人，并报告称2024年第三季度收入为10.1亿美元（同比下降1.6%）。

Thermo Fisher Scientific axes 300 at its Cambridge and Plainville, Massachusetts, viral vector sites by March 30, following 160 cuts across three sites announced in November 2024, despite flat full-year revenue of $42.8 billion..

截至3月30日，赛默飞世尔科技公司在其位于马萨诸塞州剑桥和普兰维尔的病毒载体工厂裁员300人，此前公司曾在2024年11月宣布在三个地点裁员160人，尽管全年营收持平，达428亿美元。

Epigenomics and Other Emerging Tech

表观基因组学及其他新兴技术

Emerging tech firms face cash crunches. Omega Therapeutics in Cambridge, Massachusetts, cuts up to 17 staff—leaving about 40 after a 35% cut in 2024—as it nears bankruptcy with a $1.4 million Flagship Pioneering bridge loan, despite a Novo Nordisk obesity deal, with funds only to Q2 2025.

新兴科技公司面临现金紧缩。马萨诸塞州剑桥的Omega Therapeutics裁员多达17人，此前2024年已裁员35%，目前仅剩约40人。尽管与诺和诺德达成肥胖症协议，但该公司正接近破产，依靠旗舰先锋公司提供的140万美元过渡贷款，资金仅能维持到2025年第二季度。

This February 2025 snapshot reflects a

此 2025 年 2 月的快照反映了一个

biotech and pharma landscape

生物技术和制药领域格局

adapting to clinical, financial, and strategic pressures, with companies recalibrating teams to align with their most promising or sustainable paths forward.

适应临床、财务和战略压力，企业正在重新调整团队，以与其最有希望或可持续的发展路径保持一致。